In 2014, so called “Right to Try” laws, which gave
terminally ill patients access to investigational medications, were
enacted in five states. More state legislatures are now considering such
laws. While time will tell whether these investigational drugs
have any significant impact on quality of life or longevity, the
legislative debate over such laws must be more informed than
it has been, argues Rebecca Dresser, JD, expert in biomedical ethics and law at Washington
University in St. Louis.